Neuroscience vs. Free Will

Dec 27, 2006

We know it's supposed to be a light week, but that hasn't stopped The Economist from weighing in on problems of free will in light of modern neuroscience:

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Test Evaluations

UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.

Justification for Stricter Standards Sought

The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.

Concerns Over Comment

President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.

PLOS Papers on Tremor Condition, Medical Plant Populations, Brewing Yeast Transcriptomics

In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.

Featured White Papers

Improving POC Device Manufacturability – 5 Expert Approaches

Cell Line Authentication Using the GenePrint 10 and GenePrint 24 Systems

Genomic Surveillance of SARS-CoV-2 Strains in the Greater NYC Area

How to Choose a Molecular Diagnostics Supplier

Oct

01

Featured Webinar

Immune Repertoire Sequencing to Uncover SARS-CoV-2-Specific T Cell Responses and Dynamics

T cells are the adaptive immune system’s first responders to any virus, circulating in the blood to detect and quickly multiply to attack the virus, and also support the development of antibodies by B cells.

Oct

06

Featured Webinar

Understanding Human Pulmonary Fibrosis using Single-Cell Technologies

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterized by irreversible scarring of the distal lung, leading to respiratory failure.

Oct

21

Featured Webinar

Target Enrichment NGS Panel Outperforms the Gold Standard for Sequence and CNV Analysis

Target enrichment has been a major driver behind the clinical adoption of next-generation sequencing (NGS) over the last decade because it simplifies analysis and provides a cost-effective method of massive parallel resequencing. It has not only replaced Sanger sequencing, but it is actively dispensing the need for parallel copy number variant (CNV) analysis using classic techniques.

Menu